BUSINESS COMBINATIONS (Tables)

9 Months Ended

Jun. 30, 2021

Pre-Clinical Research Services, Inc.

Business Acquisition [Line Items]

Schedule of purchase price allocation

	Allocation as of
	June 30, 2021
Assets acquired and liabilities assumed:
Receivables	$	578
Property and equipment		2,836
Unbilled receivables		162
Prepaid expenses		27
Intangible assets		2,081
Goodwill		751
Accounts payable		(109)
Accrued expenses		(118)
Customer advances		(351)
	$	5,857

HistoTox Labs

Business Acquisition [Line Items]

Schedule of purchase price allocation

	Preliminary
	Allocation as of
	June 30, 2021
Assets acquired and liabilities assumed:
Receivables		1,020
Prepaid expenses		40
Operating lease ROU		2,239
Property and equipment		4,021
Intangible assets		8,500
Other Assets		35
Goodwill		9,386
Accounts payable		(128)
Customer advances		(553)
Operating lease liability		(2,239)
	$	22,321

Bolder BioPATH

Business Acquisition [Line Items]

Schedule of purchase price allocation

	Preliminary
	Allocation as of
	June 30, 2021
Assets acquired and liabilities assumed:
Cash and cash equivalents	$	124
Receivables		2,278
Unbilled receivables		1,867
Prepaid expenses		103
Operating lease ROU		2,750
Property and equipment		6,609
Intangible assets		12,500
Other assets		70
Goodwill		36,863
Accounts payable		(93)
Accrued expenses		(279)
Deferred revenue		(723)
Deferred tax liability		(4,867)
Operating lease liability		(2,750)
	$	54,452

Schedule of unaudited pro forma information

	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
	June 30, 2021		June 30, 2020		June 30, 2021		June 30, 2020
Total revenues	$	24,786	$	21,448	$	72,789	$	62,661
Net income (loss)		(1,847)		5,242		(428)		5,863